Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.
Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
BMJ Open. 2022 Apr 1;12(4):e054638. doi: 10.1136/bmjopen-2021-054638.
Although several studies have investigated the association between fibrinogen level and the risk of cardiovascular disease (CVD), few studies have been conducted in Asia.
We conducted a community-based prospective cohort study in the Chin-Shan community, Taiwan.
A total of 2222 participants (54.6±11.9 years, 53.4% women, and 22.4 years of follow-up) who underwent plasma fibrinogen measurements and were without CVD at baseline were recruited, among which 735 participants with available C reactive protein (CRP) were included in the joint analysis of the association of fibrinogen and CRP levels with the risk of CVD.
Fibrinogen and CRP levels were measured by clotting and high-sensitivity immunoturbidimetric assays, respectively. The study outcomes were CVD events and all-cause death. Our definition of CVD included both coronary artery disease (CAD) and stroke cases. Cox proportional hazards regression models were used to estimate the HRs and 95% CIs.
Compared with the lowest quartile, participants with higher fibrinogen levels tended to have a higher risk of CAD (adjusted HR for the highest quartile=1.48 (95% CI 0.90 to 2.44); test for trend p0.037) regardless of CRP level (adjusted HR=2.12 (95% CI 1.24 to 3.63) and 2.17 (95% CI 1.06 to 4.44) for high fibrinogen/low CRP and high fibrinogen/high CRP, respectively). The association was not observed for stroke (adjusted HR for the highest quartile=0.99 (95% CI 0.62 to 1.60); test for trend p0.99) and was only observed for all-cause death among participants <65 years of age (adjusted HR for the highest quartile=1.47 (95% CI 1.11 to 1.95); test for trend p0.004).
Fibrinogen may be a potential risk factor for CAD but not for stroke. Further studies are necessary to clarify the differences in the role of fibrinogen levels on the risk of CVD between Asian and Western countries.
尽管已有多项研究探讨了纤维蛋白原水平与心血管疾病(CVD)风险之间的关系,但在亚洲进行的此类研究较少。
我们在台湾的 Chin-Shan 社区进行了一项基于社区的前瞻性队列研究。
共招募了 2222 名基线时无 CVD 且接受过血浆纤维蛋白原检测的参与者(年龄 54.6±11.9 岁,女性占 53.4%,随访 22.4 年),其中 735 名有 C 反应蛋白(CRP)数据的参与者被纳入纤维蛋白原和 CRP 水平与 CVD 风险关联的联合分析。
纤维蛋白原和 CRP 水平分别通过凝固法和高敏免疫比浊法测定。研究结局为 CVD 事件和全因死亡。我们将 CVD 定义为包括冠心病(CAD)和卒中病例。采用 Cox 比例风险回归模型估计 HR 和 95%CI。
与最低四分位相比,纤维蛋白原水平较高的参与者 CAD 风险较高(最高四分位的调整 HR=1.48(95%CI 0.90 至 2.44);趋势检验 p=0.037),无论 CRP 水平如何(高纤维蛋白原/低 CRP 组的调整 HR=2.12(95%CI 1.24 至 3.63)和高纤维蛋白原/高 CRP 组的调整 HR=2.17(95%CI 1.06 至 4.44))。但与卒中无关(最高四分位的调整 HR=0.99(95%CI 0.62 至 1.60);趋势检验 p=0.99),仅在年龄<65 岁的参与者中观察到全因死亡(最高四分位的调整 HR=1.47(95%CI 1.11 至 1.95);趋势检验 p=0.004)。
纤维蛋白原可能是 CAD 的潜在危险因素,但不是卒中的危险因素。需要进一步的研究来阐明纤维蛋白原水平对亚洲和西方国家 CVD 风险的作用差异。